Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171 — PET studies in rhesus monkey

Two high affinity and selective NK1-receptor antagonists, GR203040 and GR205171, were labelled with 11C and used in a series of experiments in rhesus monkeys. The purpose of these studies was to evaluate the brain uptake pattern and to explore the potential use of these compounds as PET ligands to characterise NK1-receptor binding. Seventeen studies were carried out with [11C]GR205171 and five experiments with [11C]GR203040, including baseline studies and studies performed after a 5 min infusion of cold compound at doses between 0.05 and 1 mg/kg. Both compounds demonstrated a significant and rapid uptake in the brain, but the uptake of [11C]GR205171 was more than double the uptake of [11C]GR203040. At tracer doses of [11C]GR205171 and all doses of [11C]GR203040 the uptake reached a plateau with no washout during the examination time, whereas [11C]GR205171 after pre-treatment with cold GR205171 showed a significant washout. Using a model with the cerebellum as reference, a method for quantitation was applied to the studies with [11C]GR205171 and the results indicated that the highest specific binding was in the striatum. The pre-treatment dose of cold GR205171 needed for 50% inhibition of binding was less than 0.04 mg/kg. The studies indicated that [11C]GR205171 could be used for the in vivo characterisation of NK1-receptor binding.

[1]  P. Ward,et al.  Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity. , 1995, Journal of medicinal chemistry.

[2]  Gavin Kilpatrick,et al.  GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity , 1996, Regulatory Peptides.

[3]  R. Hagan,et al.  The pharmacology of GR203040, a novel, potent and selective non‐peptide tachykinin NK1 receptor antagonist , 1995, British journal of pharmacology.

[4]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  N. Volkow,et al.  Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease , 1993, Neurology.

[6]  T. Visser,et al.  In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[8]  M. Bergström,et al.  MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography , 1997, European Journal of Clinical Pharmacology.

[9]  Gavin Kilpatrick,et al.  The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040 , 1995, British journal of pharmacology.

[10]  D. Gildersleeve,et al.  Synthesis of a nonpeptide carbon-11 labeled substance P antagonist for PET studies. , 1993, Nuclear medicine and biology.

[11]  J. Palacios,et al.  Phylogeny of tachykinin receptor localization in the vertebrate central nervous system: apparent absence of neurokinin-2 and neurokinin-3 binding sites in the human brain , 1991, Brain Research.

[12]  E. Rota Kops,et al.  Performance characteristics of an eight-ring whole body PET scanner. , 1990, Journal of computer assisted tomography.